LevelBlue says QuimaRAT uses encrypted plugins, OS-specific persistence, and JNA libraries to control Windows, Linux, and macOS systems.

The government renewed its commitment to bolstering electricity system reliability to prevent recurrence of recent outages in ...

Azul, the trusted leader in enterprise Java for today’s AI and cloud-first world, today launched a free JVM vulnerability ...

As enterprises embrace agentic AI and vibe coding, Secure Code Warrior CEO and co-founder Pieter Danhieux warns that ...

Despite wide availability of biologic drugs for asthma, use of these injectable medicines remains low — patients just dislike frequent injections. Generate Biomedicine’s lead drug candidate could ...

Generate:Biomedicines is the latest biotech to benefit from a renewed appetite from investors for publicly listed drug developers. Generate—which will list its stock on the Nasdaq this morning under ...

Generate Biomedicines Inc. raised $400 million in an initial public offering, pricing its shares at the midpoint of the marketed range. The Somerville, Massachusetts-based drug developer sold 25 ...

Feb 23 (Reuters) - Drug developer Generate Biomedicines said on Monday it was targeting a valuation of up to $2.17 billion in its U.S. initial public offering, tapping into a resurgent biotech market ...

Generate Biomedicines Inc., a biotechnology firm using artificial intelligence in drug development, is seeking to raise as much as $425 millon in an initial public offering, as listing activity in the ...